Rigel has a long-standing collaboration with Daiichi-Sankyo (Daiichi) for developing murine double minute 2 (MDM2) protein inhibitors in cancer, which were discovered in Rigel’s laboratories.

Preliminary safety and efficacy data from an early Phase 1 study of DS-3032, an oral selective MDM2 inhibitor, in hematological malignancies suggests that it may be a promising potential treatment for relapsed/refractory AML and high-risk MDS.

Rigel received an upfront payment and will receive milestone payments over the life of the partnership, as well as royalties on net sales of any commercialized products to emerge from the collaboration.

Development of DS-3032:

  • In December 2016, announced encouraging preliminary safety and efficacy data from a Phase 1 study of DS-3032
  • Currently, three ongoing Phase 1 clinical trials to explore the appropriate dose and treatment schedule of DS-3032, as well as efficacy and safety in combination with other therapies, including TAVALISSE